- Hong
Kon g Banks | NEUTRAL
- Wing
Hang Bank (302 HK) | Dropping Coverage
- Cairn
India (CAIR IN) | Results Review
- Havells
India (HAVL IN) | Rating Change
- Larsen
& Toubro (LT IN) | Results Review
- UMW
Holdings (UMWH MK) | Company Update
- Raffles
Medical (RFMD SP) | Results Review
- Union
Bank of the Philippines (UBP PM) | Results Review
- Bumrungrad
Hospital (BH TB) | Results Preview
- Khonburi
Sugar (KBS TB) | Results Preview
|
Hong Kon g Banks | NEUTRAL
|
Sector Update
|
1H looks good, but lofty
valuations
|
- Market
expects 1H14 net profit growth of 3-14% YoY
- Solid
loan growth, widening NIM; Weak non-interest income.
- Slight
rise in credit costs. NEUTRAL. Top Picks DSB & DSF.
|
Wing Hang Bank (302 HK) |
Dropping Coverage
|
Delisting on successful
acquisition
|
Share Price: HKD121.80 | Target
Price: HKD126.62(+4%) | MCap (USD): 4.8B | ADTV (USD): 12M
|
- OCBC
has acquired 97.52% of WHB.
- There
will be compulsory acquisition on the remaining shares
- of
WHB.
- WHB
will be delisted from HKEx. Dropping coverage.
|
Cairn India (CAIR IN) | Results
Review
|
Production and reserves improving
|
Share Price: INR309 | Target
Price: INR400(+29%) | MCap (USD): 9.8B | ADTV (USD): 17M
|
- Maintain
BUY and DCF-based TP of INR400. Investors sold down the stock
(-12%) in the last three days on concerns of a INR48b loan
given to a group company.
- 1Q
recurring EPS of INR14.5 above Street expectations but in line
w/ our estimate. We cut our FY15 EPS estimate due to change in
deprec. policy and higher cost of exploration. Our new INR60
EPS for FY15 is 10% lower than prev. forecast.
- CAIR�s 5.1x PER, 0.8x P/B and 4%
div. yield are compelling and shield against a material
downside in the stock. Although we do not support CAIR�s decision to lend to a
group company, we believe it is a temporary distraction.
Production and reserves, which are improving, will be back in
focus.
- (FULL
NOTE WILL BE OUT SOON)
|
Havells India (HAVL IN) | Rating
Change
|
Earnings growth potential
priced-in
|
Share Price: INR1,237 | Target
Price: INR1,126(-9%) | MCap (USD): 2.6B | ADTV (USD): 6M
|
- We
downgrade HAVL to HOLD from BUY as current PER of 22x FY16F
(vs 3-yr avg of 15x) factors in the strong earnings potential.
- HAVL�s stock is up 53%+ Y-T-D. At
its analyst call, HAVL re-iterated its positive outlook and
gave growth guidance for FY15 at 15% on expectations of
improved consumer sentiment and a pick-up in industrial
activity in 2HF15.
- We
think this is factored in for now and we look forward for
event that could generate an incremental trigger like
acquisition in domestic market.
- (FULL
NOTE WILL BE OUT SOON)
|
Larsen & Toubro (LT IN) |
Results Review
|
Share Price: INR1,656 | Target
Price: INR2,000(+21%) | MCap (USD): 25.5B | ADTV (USD): 61M
|
Starts FY15 with a bang
|
- Recurring
earnings are in line with our estimates with revenue +5% YoY,
EBITDA +140bp YoY, and profit +10% YoY.
- Order
inflow increased 10% YoY. Order book now stands at INR1.9t
(1.8x FY15F revenue).
- One-time
gain of INR8.6b from stake sale in the finance and ports
businesses boosted reported EPS growth of 100%. We maintain
BUY with SOTP-based TP of INR2,000.
- (FULL
NOTE WILL BE OUT SOON)
|
UMW Holdings (UMWH MK) | Company
Update
|
Rationalising non-core M&E
assets
|
Share Price: MYR11.70 | Target
Price: MYR12.44 (+6%) | MCap (USD): 4.3B
|
- UMWH�s disposal of non-core
M&E assets in India is positive,
- in
line with its strategy to streamline its core operations.
- No
change to our earnings from this development; potential
- upside
from stronger-than-expected Toyota vehicle sales.
- Reiterate
BUY with an unchanged MYR12.44 SOTP-based TP.
|
Raffles Medical (RFMD SP) |
Results Review
|
Short-term murkiness
|
Share Price: SGD3.95 | Target
Price: SGD3.94(-0%) | MCap (USD): 1.8B | ADTV (USD): 1M
|
- Key
negative: The lucrative hospital services posted its second
consecutive quarter of slow YoY growth.
- No
clarity over expansion plans in China, while a new rival in
Singapore is emerging.
- HOLD
with unchanged DCF-derived TP of SGD3.94.
|
Union Bank of the Philippines
(UBP PM) | Results Review
|
Core lending supports weak
trading
|
Share Price: PHP118.00 | Target
Price: PHP127.00(+8%) | MCap (USD): 1.7B | ADTV (USD): 0.1M
|
- Maintain
HOLD with share price upside of just 8%.
- Earnings
in 2Q14 down 25% YoY to PHP1.6b due to a 75% drop in treasury
gains to PHP566m.
- Net
interest income increased 33% with 23% loan growth amid better
funding mix.
- (FULL
NOTE WILL BE OUT SOON)
|
Bumrungrad Hospital (BH TB) |
Results Preview
|
Single digit growth
|
Share Price: THB122.00 | Target
Price: THB115.00(-6%) |MCap (USD): 2.8B | ADTV (USD): 5M
|
- Price
could increase 9% YoY to offset 5% YoY drop in overall patient
traffic. Hospital revenue is expected to jump 4% YoY. EBITDA
margin could be maintained at 27%.
- Forecast
2Q14F net profit of THB620m, -3% QoQ and 7% YoY, this would be
23% of our FY14 projection. Earnings growth driven by annual
price adjustment and rising price intensity.
- Maintain
HOLD with TP of THB115, based on DCF at 8.5% WACC and 3%
terminal growth. Our TP implies 2015F multiples (fully dilute)
are 34x PER, 7x PBV, and 1.4x PEG.
- (FULL
NOTE WILL BE OUT SOON)
|
Khonburi Sugar (KBS TB) | Results
Preview
|
Outlook turning lacklustre; HOLD
|
Share Price: THB11.80 | Target
Price: THB12.60(+7%) | MCap (USD): 204M | ADTV (USD): 0.5M
|
- Maintain
non-consensus HOLD, DCF-based TP of THB12.60. 2Q14 earnings
expected to drop 8% YoY on weaker prices and lower volume
sales; If met, 1H14 will be 78% of FY forecast and that is
fine as 4Q tends to be a loss-making quarter.
- The
sugar market has turned sluggish due to high carry over
inventory and good harvest. The demand-driven price recovery
has now gone free fall. The prospect of earnings upgrade is
limited at this point.
|
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.